IE 11 is not supported. For an optimal experience visit our site on another browser.
CEO behind HIV drug Truvada grilled on $3B in profits
May 17, 201902:23
  • UP NEXT

    New HHS rules target care for transgender minors

    02:22

  • Supreme Court appears skeptical of LGBTQ conversion therapy bans

    04:02

  • Iconic rainbow crosswalk removed in Miami Beach amid protests

    02:13

  • Volunteers use chalk to restore crosswalk honoring Pulse shooting victims

    02:32

  • Hate mail targets Ohio homes displaying Pride flags

    01:36

  • NFL veteran hosts LGBTQ+ friendly football camp

    02:42

  • 'Let Them Stare' offers coming-of-age tale for a new generation

    03:00

  • Two wounded when gunfire erupts near NYC Pride festivities

    01:51

  • Pride Month concludes with fewer corporate sponsors amid DEI pushback

    01:34

  • Supreme Court upholds Tennessee ban on youth gender-affirming care

    05:27

  • Daniel Martin shares his journey as an Asian-American beauty industry trailblazer

    03:45

  • Community angered over Washington's Dupont Circle Park closure during WorldPride

    02:10

  • Nebraska becomes latest state to ban transgender students from girls sports

    00:28

  • California imposes new transgender athlete policy

    03:39

  • Companies pull funding, support from Pride events fearing backlash

    04:00

  • Trump threatens school's funding over trans athlete competing in California track finals

    04:13

  • Transgender student's track meet win sparks heated debate

    01:17

  • Yosemite climbers display transgender pride flag on iconic El Capitan

    00:41

  • Lesbian teen attacked inside Illinois McDonald's

    01:38

  • Plaintiff in landmark same-sex marriage case warns of threats to marriage equality

    03:55

CEO behind HIV drug Truvada grilled on $3B in profits

NBC News Clone summarizes the latest on: Ceo Behind Hiv Drug Truvada Grilled On 3b In Profits 59819077674 - Breaking News | NBC News Clone. This article is rewritten and presented in a simplified tone for a better reader experience.

02:23

Daniel O’Day, the chairman and CEO of Gliead Sciences Inc., is asked to explain U.S. pricing of HIV prevention drug Truvada for PrEP along with his company’s profits and his $30M signing bonus.May 17, 2019

Get more newsCeo Behind Hiv Drug Truvada Grilled On 3b In Profits 59819077674 - Breaking News | NBC News Cloneon
  • UP NEXT

    New HHS rules target care for transgender minors

    02:22

  • Supreme Court appears skeptical of LGBTQ conversion therapy bans

    04:02

  • Iconic rainbow crosswalk removed in Miami Beach amid protests

    02:13

  • Volunteers use chalk to restore crosswalk honoring Pulse shooting victims

    02:32

  • Hate mail targets Ohio homes displaying Pride flags

    01:36

  • NFL veteran hosts LGBTQ+ friendly football camp

    02:42
Get more newsLiveon

Best of NBC News

Play All
Play All
×
AdBlock Detected!
Please disable it to support our content.

Related Articles

Donald Trump Presidency Updates - Politics and Government | NBC News Clone | Inflation Rates 2025 Analysis - Business and Economy | NBC News Clone | Latest Vaccine Developments - Health and Medicine | NBC News Clone | Ukraine Russia Conflict Updates - World News | NBC News Clone | Openai Chatgpt News - Technology and Innovation | NBC News Clone | 2024 Paris Games Highlights - Sports and Recreation | NBC News Clone | Extreme Weather Events - Weather and Climate | NBC News Clone | Hollywood Updates - Entertainment and Celebrity | NBC News Clone | Government Transparency - Investigations and Analysis | NBC News Clone | Community Stories - Local News and Communities | NBC News Clone